BR112013005907A2 - composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica - Google Patents

composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica

Info

Publication number
BR112013005907A2
BR112013005907A2 BR112013005907A BR112013005907A BR112013005907A2 BR 112013005907 A2 BR112013005907 A2 BR 112013005907A2 BR 112013005907 A BR112013005907 A BR 112013005907A BR 112013005907 A BR112013005907 A BR 112013005907A BR 112013005907 A2 BR112013005907 A2 BR 112013005907A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
preventing
methods
hiv infection
Prior art date
Application number
BR112013005907A
Other languages
English (en)
Other versions
BR112013005907B1 (pt
Inventor
Deepak B Mundhra
Rennan Pan
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of BR112013005907A2 publication Critical patent/BR112013005907A2/pt
Publication of BR112013005907B1 publication Critical patent/BR112013005907B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica. a presente invenção se refere às composições farmacêuticas de (3s,11ar)-n-[2,4-difluorofenil)metil]-2,3,5,11,11 a-hexadridro-6-hidróxi-3-metil-5,7-dioxo-oxazol[3,2-a]pirido[1,2-d]pirazino-8-carboxamida, úteis no tratamento ou prevenção das infecções pelo vírus da imunodeficiência humana (hiv).
BR112013005907-9A 2010-09-16 2011-09-15 Composição farmacêutica parenteral BR112013005907B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38354110P 2010-09-16 2010-09-16
US61/383,541 2010-09-16
PCT/US2011/051713 WO2012037320A2 (en) 2010-09-16 2011-09-15 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR112013005907A2 true BR112013005907A2 (pt) 2016-06-07
BR112013005907B1 BR112013005907B1 (pt) 2021-04-27

Family

ID=45832235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005907-9A BR112013005907B1 (pt) 2010-09-16 2011-09-15 Composição farmacêutica parenteral

Country Status (28)

Country Link
US (3) US20130171214A1 (pt)
EP (1) EP2616076B1 (pt)
JP (1) JP6231385B2 (pt)
KR (1) KR101938662B1 (pt)
CN (1) CN103547266B (pt)
AU (1) AU2011302030B2 (pt)
BR (1) BR112013005907B1 (pt)
CA (1) CA2810524C (pt)
CL (1) CL2013000715A1 (pt)
CY (1) CY1118279T1 (pt)
DK (1) DK2616076T3 (pt)
EA (1) EA024924B1 (pt)
ES (1) ES2594557T3 (pt)
HR (1) HRP20161280T1 (pt)
HU (1) HUE031336T2 (pt)
IL (1) IL225028A (pt)
LT (1) LT2616076T (pt)
ME (1) ME02520B (pt)
MX (1) MX346193B (pt)
PL (1) PL2616076T3 (pt)
PT (1) PT2616076T (pt)
RS (1) RS55222B1 (pt)
SI (1) SI2616076T1 (pt)
SM (1) SMT201600350B (pt)
TW (1) TWI577377B (pt)
UA (1) UA108250C2 (pt)
WO (1) WO2012037320A2 (pt)
ZA (1) ZA201301766B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN104902905A (zh) * 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CA2961528A1 (en) * 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CA2969303A1 (en) * 2014-12-20 2016-06-23 Troikaa Pharmaceuticals Limited Injectable formulations of paracetamol
WO2017223280A2 (en) * 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4234561A3 (en) 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN109646440B (zh) * 2019-01-11 2021-04-20 山东省农业科学院奶牛研究中心 Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用
HRP20221074T1 (hr) 2019-03-22 2022-11-11 Gilead Sciences, Inc. Premošteni triciklički spojevi karbamoilpiridona i njihove farmaceutske uporabe
TW202135815A (zh) * 2019-12-09 2021-10-01 美商 Ｖｉｉｖ 醫療保健公司 醫藥組合物
AU2021225809B2 (en) 2020-02-24 2023-08-24 Gilead Sciences, Inc. Tetracyclic compounds for treating HIV infection
WO2022008644A1 (en) * 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
US20230321089A1 (en) * 2020-09-01 2023-10-12 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
CN115844838B (zh) * 2022-12-01 2023-10-24 浙江萃泽医药科技有限公司 一种可注射的药物组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1215599A (fr) * 1958-06-27 1960-04-19 Rhone Poulenc Sa Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
KR100571215B1 (ko) 1995-06-07 2006-10-24 트라이머리스 인코퍼레이티드 복합적인치료요법을이용한hiv와다른바이러스감염의치료
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
JP5160005B2 (ja) * 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
IL166156A0 (en) * 2002-07-09 2006-01-15 Point Therapeutics Inc Boroproline compound combination therapy
US7842232B2 (en) 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
HUE044978T2 (hu) * 2005-04-28 2019-11-28 Viiv Healthcare Co HIV integráz gátló aktivitású policiklusos karbamoilpiridon származék
WO2007053189A2 (en) * 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP5701057B2 (ja) * 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー （ｅ）４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの結晶形
KR20100099292A (ko) * 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2607403T3 (es) * 2008-07-25 2017-03-31 Shionogi & Co., Ltd. Compuestos químicos como intermedios sintéticos
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
WO2011017395A1 (en) 2009-08-04 2011-02-10 Glaxosmithkline Llc Chemical compounds
US20110152303A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Chemical Compounds

Also Published As

Publication number Publication date
MX2013003037A (es) 2013-09-02
HUE031336T2 (hu) 2017-07-28
CY1118279T1 (el) 2017-06-28
EA201390233A1 (ru) 2014-03-31
SMT201600350B (it) 2016-11-10
UA108250C2 (uk) 2015-04-10
ZA201301766B (en) 2016-11-30
JP6231385B2 (ja) 2017-11-15
CA2810524C (en) 2018-06-26
MX346193B (es) 2017-03-10
CN103547266B (zh) 2016-04-06
WO2012037320A2 (en) 2012-03-22
KR101938662B1 (ko) 2019-01-15
RS55222B1 (sr) 2017-02-28
JP2014500849A (ja) 2014-01-16
US20170027933A1 (en) 2017-02-02
IL225028A (en) 2017-04-30
HRP20161280T1 (hr) 2016-11-18
SI2616076T1 (sl) 2016-11-30
BR112013005907B1 (pt) 2021-04-27
AU2011302030A1 (en) 2013-04-04
TWI577377B (zh) 2017-04-11
CA2810524A1 (en) 2012-03-22
US20130171214A1 (en) 2013-07-04
EP2616076A4 (en) 2015-01-21
LT2616076T (lt) 2016-10-10
DK2616076T3 (en) 2016-10-24
PT2616076T (pt) 2016-09-30
CN103547266A (zh) 2014-01-29
CL2013000715A1 (es) 2013-07-05
ES2594557T3 (es) 2016-12-21
US20220096469A1 (en) 2022-03-31
EA024924B1 (ru) 2016-11-30
PL2616076T3 (pl) 2017-07-31
TW201223529A (en) 2012-06-16
EP2616076A2 (en) 2013-07-24
WO2012037320A3 (en) 2014-03-27
ME02520B (me) 2017-02-20
KR20130116254A (ko) 2013-10-23
AU2011302030B2 (en) 2015-01-22
EP2616076B1 (en) 2016-07-13
US11224597B2 (en) 2022-01-18

Similar Documents

Publication Publication Date Title
BR112013005907A2 (pt) composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
NZ598766A (en) Macrocyclic integrase inhibitors
PH12016500389B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
NZ627827A (en) Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
MY192716A (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
EA201792516A1 (ru) Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
BR112013000296A2 (pt) agentes terapêuticos 976
UA107155C2 (uk) Стабільна композиція для лікування герпесвірусних інфекцій
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
EP2606885A4 (en) "RENESSANS" MEDICINAL PREPARATION WITH ANTIBACTERIAL, ANTI-ULCER AND IMMUNOMODULATORY ACTION
BRPI1008671A2 (pt) polipeptídeo modificado, composição aquosa, conjugado, polinucleotídeo, trímero, vetor de expressão, célula hospedeira, composição antigênica ou imunogênica, preparação farmacêutica, uso de pelo menos um polipeptídeo, e método de tratamento e/ou profilaxia contra uma infecção por iv.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2011, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO BRASILEIRA INTERDISCIPLINAR DE AIDS, GRUPO DE INCENTIVO A VIDA - GIV, UNIVERSIDADES ALIADAS PARA O ACESSO A MEDICAMENTOS ESSENCIAIS - UAEM/BRASIL, GRUPO SOLIDARIEDADE E VIDA - 870210098145 - 25/10/2021